Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eramax Vet
- Development stage
- Unknown
- Lead developer
- Navana Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eramax Vet is a veterinary fixed-dose combination powder developed by Navana Pharmaceuticals for oral administration in poultry. It contains five active ingredients: erythromycin (a macrolide antibiotic), neomycin (an aminoglycoside antibiotic), sulfadimidine (a sulfonamide antibiotic), trimethoprim (a dihydrofolate reductase inhibitor), and bromhexine (a mucolytic agent). This combination is indicated for the treatment of various respiratory and enteric bacterial conditions in poultry, including chronic respiratory disease (CRD), complicated chronic respiratory disease (CCRD), bronchopneumonia, infectious coryza, colibacillosis, fowl cholera, salmonellosis, diarrhea, enteritis, and staphylococcal infections. Erythromycin and neomycin inhibit bacterial protein synthesis by binding to the 50S and 30S ribosomal subunits, respectively. Sulfadimidine and trimethoprim act synergistically to block bacterial folic acid synthesis, while bromhexine acts as a secretolytic expectorant to reduce mucus viscosity and facilitate clearance.
- Brand names
- Eramax Vet
- Other names
- Erythromycin + Neomycin + Sulfadimidine + Trimethoprim + BromhexineErythromycin Stearate + Neomycin Sulfate + Sulphadimidine + Trimethoprim + Bromhexine HydrochlorideErythromycin, Neomycin, Sulfadimidine, Trimethoprim & Bromhexine
02
Targets
Bacterial RibosomeBacterial 50S ribosomal subunitDHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on Eramax Vet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eramax Vet.